Issue 3/2008
Content (12 Articles)
The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro
Malin Wickström, Caroline Haglund, Henrik Lindman, Peter Nygren, Rolf Larsson, Joachim Gullbo
Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan
Murugesan K. Gounder, Ahamed S. Nazar, Ahamed Saleem, Pooja Pungaliya, Diptee Kulkarni, Richard Versace, Eric H. Rubin
Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells
Axel-Rainer Hanauske, Ulrike Eismann, Olaf Oberschmidt, Heike Pospisil, Hartmut M. Hanauske-Abel, Johannes Blatter, Doreen Ma, Victor Chen, Michael Lahn
A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines
Piotr Jasinski, Brandon Welsh, Jorge Galvez, David Land, Pawel Zwolak, Lori Ghandi, Kaoru Terai, Arkadiusz Z. Dudek
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia
Olatoyosi M. Odenike, Richard A. Larson, Devika Gajria, M. Eileen Dolan, Shannon M. Delaney, Theodore G. Karrison, Mark J. Ratain, Wendy Stock
A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas
Emily Chan, Daniel Mulkerin, Mace Rothenberg, Kyle D. Holen, A. Craig Lockhart, James Thomas, Jordan Berlin
A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial
Christopher W. Lee, Karl Bélanger, Sanjay C. Rao, Teresa M. Petrella, Richard G. Tozer, Lori Wood, Kerry J. Savage, Elizabeth A. Eisenhauer, Timothy W. Synold, Nancy Wainman, Lesley Seymour
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
Patricia A. Tang, Lillian L. Siu, Eric X. Chen, Sebastien J. Hotte, Stephen Chia, James K. Schwarz, Gregory R. Pond, Caitlin Johnson, A. Dimitrios Colevas, Timothy W. Synold, Lakshmi S. Vasist, Eric Winquist
A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)
Jennifer J. Knox, Sharlene Gill, Timothy W. Synold, James J. Biagi, Pierre Major, Ron Feld, Christine Cripps, Nancy Wainman, Elizabeth Eisenhauer, Lesley Seymour
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma
Premal H. Patel, G. Varuni Kondagunta, Lawrence Schwartz, Nicole Ishill, Jennifer Bacik, John DeLuca, Paul Russo, Robert J. Motzer
Extrinsic nitric oxide donor partially reverses arginine deiminase induced cell growth inhibition through NFκB and Bcl-XL
Jae Hong Seo, Hwa Jung Sung, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Bon Hong Min, Jun Suk Kim
PPAR-γ ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo
I.K. Choi, Y.H. Kim, J.S. Kim, J.H. Seo